Elevated substance P levels in HIV-infected women in comparison to HIV-negative women

AIDS Research and Human Retroviruses

Volumn 24, Issue 3, 2008, Pages 375-378

  Douglas, Steven D ^a   Cnaan, Avital ^a   Lynch, Kevin G ^b   Benton, Tami ^b   Zhao, Huaqing ^a   Gettes, David R ^b   Evans, Dwight L ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROKININ 1 RECEPTOR; SUBSTANCE P;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREGULATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; FEMALE; HIV INFECTIONS; HUMANS; MIDDLE AGED; SUBSTANCE P;

EID: 41449095167     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0207     Document Type: Article

References (37)

1. Ho WZ, Lai JP, Li Y, and Douglas SD: HIV enhances substance P expression in human immune cells. FASEB J 2002;16:616-618.
2. Douglas SD, Ho WZ, Gettes DR, et al.: Elevated substance P levels in HIV-infected men. AIDS 2001;15:2043-2045.
3. CDC: HIV/AIDS Surveillance Report, 2005. 2006;17:1-46.
4. Whitacre CC: Sex differences in autoimmune disease. Nat Immunol 2001;2:777-780.
5. Whitacre CC, Reingold SC, and O'Looney PA: A gender gap in autoimmunity. Science 1999;283:1277-1278.
6. Morrison MF, Petitto JM, Ten Have T, et al.: Depressive and anxiety disorders in women with HIV infection. Am J Psychiatry 2002;159:789-796.
7. Evans DL, Ten Have TR, Douglas SD, et al.: Association of depression with viral load, CD8 T lymphocytes, and natural killer cells in women with HIV infection. Am J Psychiatry 2002;159:1752-1759.
8. Evans DL, Folds JD, Petitto JM, et al.: Circulating natural killer cell phenotypes in men and women with major depression. Relation to cytotoxic activity and severity of depression. Arch Gen Psychiatry 1992;49:388-395.
9. Campbell DE, Raftery N, Tustin R 3rd, et al.: Measurement of plasma-derived substance P: Biological, methodological, and statistical considerations. Clin Vaccine Immunol 2006;13:1197-1203.
10. Fehder WP, Ho WZ, Campbell DE, et al.: Development and evaluation of a chromatographic procedure for partial purification of substance P with quantitation by an enzyme immunoassay. Clin Diagn Lab Immunol 1998;5:303-307.
11. Douglas SD, Durako SJ, Tustin NB, et al.: Natural killer cell enumeration and function in HIV-infected and high-risk uninfected adolescents. AIDS Res Hum Retroviruses 2001;17:543-552.
12. Azzari C, Rossi ME, Resti M, et al.: [Changed levels of substance P and somatostatin in HIV-positive children.] Pediatr Med Chir 1992;14:577-581.
13. Bost KL: Tachykinin-modulated anti-viral responses. Front Biosci 2004;9:1994-1998.
14. Ho WZ, Lai JP, Zhu XH, Uvaydova M, and Douglas SD: Human monocytes and macrophages express substance P and neurokinin-1 receptor. J Immunol 1997;159:5654-5660.
15. Ho W-Z and Douglas SD: Substance P and neurokinin-1 receptor modulation of HIV. J Neuroimmunol 2004;157:48-55.
16. Nelson DA and Bost KL: Non-neuronal mammalian tachykinin expression. Front Biosci 2004;9:2166-2176.
17. Lai JP, Ho WZ, Zhan GX, Yi Y, Collman RG, and Douglas SD: Substance P antagonist (CP-96,345) inhibits HIV-1 replication in human mononuclear phagocytes. Proc Natl Acad Sci USA 2001;98:3970-3975.
18. Tripp RA, Dakhama A, Jones LP, Barskey A, Gelfand EW, and Anderson LJ: The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P. J Virol 2003;77:6580-6584.
19. Ho WZ, Cnaan A, Li YH, et al.: Substance P modulates human immunodeficiency virus replication in human peripheral blood monocyte-derived macrophages. AIDS Res Hum Retroviruses 1996;12:195-198.
20. Lai JP, Ho WZ, Kilpatrick LE, et al.: Full-length and truncated neurokinin-1 receptor expression and function during monocyte/macrophage differentiation. Proc Natl Acad Sci USA 2006;103:7771-7776.
21. Brabazon C, Logue KJ, Burchell A, and Galli R: Gender differences in antiretroviral therapy received in Ontario: A possible effect of viral load differences. Int Conf AIDS 1998;12:801.
22. Evans JS, Nims T, Cooley J, et al.: Serum levels of virus burden in early-stage human immunodeficiency virus type 1 disease in women. J Infect Dis 1997;175:795-800.
23. Farzadegan H, Hoover DR, Astemborski J, et al.: Sex differences in HIV-1 viral load and progression to AIDS. Lancet 1998;352:1510-1514.
24. Junghans C, Ledergerber B, Chan P, Weber R, and Egger M: Sex differences in HIV-1 viral load and progression to AIDS. Swiss HIV Cohort Study. Lancet 1999;353:589.
25. Katzenstein DA, Hammer SM, Hughes MD, et al.: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med 1996;335:1091-1098.
26. Lyles CM, Vlahov D, Farzadegan H, et al.: Comparison of two measures of human immunodeficiency virus (HIV) type 1 load in HIV risk groups. J Clin Microbiol 1998;36:3647-3652.
27. Moroni M: Sex differences in HIV-1 viral load and progression to AIDS. ICONA Study Group. Italian cohort of HIV-1 positive individuals. Lancet 1999;353:589-590.
28. Foca M, Moye J, Chu C, et al.: Gender differences in lymphocyte populations, plasma HIV RNA levels, and disease progression in a cohort of children born to women infected with HIV. Pediatrics 2006;118:146-155.
29. Douglas SD, Rudy B, Muenz L, et al.: Peripheral blood mononuclear cell markers in antiretroviral therapy-naive HIV-infected and high risk seronegative adolescents. Adolescent Medicine HIV/AIDS Research Network. AIDS 1999;13:1629-1635.
30. Rudy BJ, Wilson CM, Durako S, Moscicki A-B, Muenz L, and Douglas SD: Peripheral blood lymphocyte subsets in adolescents: A longitudinal analysis from the REACH project. Clin Diagn Lab Immunol 2002;9:959-965.
31. Sterling TR, Lyles CM, Vlahov D, Astemborski J, Margolick JB, and Quinn TC: Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. J Infect Dis 1999;180:666-672.
32. Tilzey AJ, Palmer SJ, Barrow S, et al.: Clinical trial with inactivated hepatitis A vaccine and recommendations for its use. BMJ 1992;304:1272-1276.
33. Hollinger FB: Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am J Med 1989;87:36S-40S.
34. Green MS, Shohat T, Lerman Y, et al.: Sex differences in the humoral antibody response to live measles vaccine in young adults. Int J Epidemiol 1994;23:1078-1081.
35. Leon ME, Ward B, Kanashiro R, et al.: Immunologic parameters 2 years after high-titer measles immunization in Peruvian children. J Infect Dis 1993;168:1097-1104.
36. Anastos K, Schneider MF, Gange SJ, et al.: The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr 2005;39:537-544.
37. Brenchley JM, Price DA, Schacker TW, et al.: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12:1365-1371.